|
US20030017528A1
(en)
*
|
1998-11-20 |
2003-01-23 |
Ruoping Chen |
Human orphan G protein-coupled receptors
|
|
EP1133559B1
(en)
*
|
1998-11-20 |
2005-08-10 |
Arena Pharmaceuticals, Inc. |
Human orphan g protein-coupled receptor rup3
|
|
USRE42190E1
(en)
|
1998-11-20 |
2011-03-01 |
Arena Pharmaceuticals, Inc. |
Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
|
|
US7816492B2
(en)
*
|
1998-11-20 |
2010-10-19 |
Arena Pharmaceuticals, Inc. |
Human G protein-coupled receptors
|
|
US6221660B1
(en)
|
1999-02-22 |
2001-04-24 |
Synaptic Pharmaceutical Corporation |
DNA encoding SNORF25 receptor
|
|
US20030125539A1
(en)
*
|
1999-02-22 |
2003-07-03 |
Synaptic Pharmaceutical Corporation |
DNA encoding SNORF25 receptor
|
|
AU5168700A
(en)
|
1999-05-28 |
2000-12-18 |
Synaptic Pharmaceutical Corporation |
Dna encoding snorf33 receptor
|
|
GB9923177D0
(en)
*
|
1999-09-30 |
1999-12-01 |
Pfizer Ltd |
Novel polypeptide
|
|
WO2001032864A2
(en)
*
|
1999-11-03 |
2001-05-10 |
Merck Patent Gmbh |
Gpcr-kd5 polypeptides and dna sequences thereof
|
|
WO2001036473A2
(en)
*
|
1999-11-16 |
2001-05-25 |
Pharmacia & Upjohn Company |
Human g protein-coupled receptors
|
|
AU6744501A
(en)
*
|
2000-05-18 |
2001-11-26 |
Bayer Aktiengesellschaft |
Regulation of human dopamine-like g protein-coupled receptor
|
|
WO2002044362A1
(en)
*
|
2000-12-01 |
2002-06-06 |
Yamanouchi Pharmaceutical Co., Ltd. |
Method of screening remedy for diabetes
|
|
US20030064381A1
(en)
*
|
2001-03-07 |
2003-04-03 |
Feder John N. |
Polynucleotide encoding a novel human G-protein coupled receptor, HGPRBMY26, expressed highly in testis and gastrointestinal tissues
|
|
WO2002077001A2
(en)
*
|
2001-03-09 |
2002-10-03 |
Tularik Inc. |
Novel receptors
|
|
US7053121B2
(en)
*
|
2001-03-19 |
2006-05-30 |
Trustees Of The University Of Pennsylvania |
Compositions and methods for regulating circadian rhythms
|
|
EP2390308A1
(en)
|
2002-02-25 |
2011-11-30 |
Vaxiion Therapeutics Inc |
Minicell compositions and methods
|
|
CA2489405A1
(en)
*
|
2002-09-11 |
2004-03-25 |
Yamanouchi Pharmaceutical Co., Ltd. |
Screening method of agents for increasing insulin content
|
|
US20030143590A1
(en)
*
|
2002-11-18 |
2003-07-31 |
Shyam Ramakrishnan |
Regulation of human dopamine-like g protein- coupled receptor
|
|
US20080009551A1
(en)
*
|
2003-04-30 |
2008-01-10 |
Arena Pharmaceuticals, Inc. |
Methods and Compositions for Identifying Modulators of G Protein-Coupled Receptors
|
|
US7083933B1
(en)
|
2003-05-09 |
2006-08-01 |
Prosidion Limited |
Methods for identification of modulators of OSGPR116 activity
|
|
DE602004031605D1
(de)
*
|
2003-05-20 |
2011-04-14 |
Univ Glasgow |
Materialien und methoden die sich auf g-protein gekoppelte rezeptor oligomere beziehen
|
|
US7309589B2
(en)
*
|
2004-08-20 |
2007-12-18 |
Vironix Llc |
Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
|
|
NZ556017A
(en)
*
|
2004-12-24 |
2009-10-30 |
Prosidion Ltd |
G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
|
|
DOP2006000008A
(es)
*
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
|
US7306203B2
(en)
*
|
2005-01-28 |
2007-12-11 |
Platt Robert E |
Post assembly and spacer for use therewith
|
|
WO2006113236A2
(en)
*
|
2005-04-14 |
2006-10-26 |
Cornell Research Foundation, Inc. |
Novel chemical inhibitors of neutrophil activation through the sac-dependent pathway
|
|
MX2007016508A
(es)
*
|
2005-06-30 |
2008-03-04 |
Prosidion Ltd |
Agonistas del receptor acoplado a la proteina g.
|
|
EP1907383A1
(en)
*
|
2005-06-30 |
2008-04-09 |
Prosidion Limited |
Gpcr agonists
|
|
DK1971862T3
(da)
*
|
2006-04-11 |
2011-02-14 |
Arena Pharm Inc |
Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person
|
|
PE20071221A1
(es)
*
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
|
US7638541B2
(en)
*
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
|
AR064735A1
(es)
*
|
2007-01-04 |
2009-04-22 |
Prosidion Ltd |
Agonistas de gpcr y composicion farmaceutica en base al compuesto
|
|
PE20081849A1
(es)
|
2007-01-04 |
2009-01-26 |
Prosidion Ltd |
Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
|
|
GB0700122D0
(en)
|
2007-01-04 |
2007-02-14 |
Prosidion Ltd |
GPCR agonists
|
|
US20100048625A1
(en)
*
|
2007-01-04 |
2010-02-25 |
Matthew Colin Thor Fyfe |
Piperidine gpcr agonists
|
|
RS52065B
(sr)
|
2007-01-04 |
2012-06-30 |
Prosidion Ltd |
Piperidinski gpcr agonisti
|
|
CA2693169C
(en)
*
|
2007-07-19 |
2016-01-12 |
Metabolex, Inc. |
N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
|
|
WO2009034388A1
(en)
|
2007-09-10 |
2009-03-19 |
Prosidion Limited |
Compounds for the treatment of metabolic disorders
|
|
CN101801954B
(zh)
*
|
2007-09-20 |
2013-10-09 |
Irm责任有限公司 |
作为gpr119活性调节剂的化合物和组合物
|
|
GB0720389D0
(en)
|
2007-10-18 |
2008-11-12 |
Prosidion Ltd |
G-Protein Coupled Receptor Agonists
|
|
GB0720390D0
(en)
|
2007-10-18 |
2007-11-28 |
Prosidion Ltd |
G-Protein coupled receptor agonists
|
|
CL2009000782A1
(es)
*
|
2008-03-31 |
2010-04-30 |
Metabolex Inc |
Metodo que comprende un compuesto derivado de oximetilen-arilo sustituido, inhibidores de dpp-iv; y su uso en el tratamiento de la diabetes y disminucion de trigliceridos, entre otras enfermedades.
|
|
EP2146210A1
(en)
*
|
2008-04-07 |
2010-01-20 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
|
|
GB0812649D0
(en)
*
|
2008-07-10 |
2008-08-20 |
Prosidion Ltd |
Compounds
|
|
ATE557024T1
(de)
*
|
2008-07-10 |
2012-05-15 |
Prosidion Ltd |
Piperidinverbindungen als gpcr-agonisten
|
|
GB0812648D0
(en)
*
|
2008-07-10 |
2008-08-20 |
Prosidion Ltd |
Compounds
|
|
GB0812642D0
(en)
*
|
2008-07-10 |
2008-08-20 |
Prosidion Ltd |
Compounds
|
|
US20110160222A1
(en)
*
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
|
US8742117B2
(en)
|
2008-12-24 |
2014-06-03 |
Cadila Healthcare Limited |
Oxime derivatives
|
|
GB0904287D0
(en)
|
2009-03-12 |
2009-04-22 |
Prosidion Ltd |
Compounds for the treatment of metabolic disorders
|
|
GB0904285D0
(en)
|
2009-03-12 |
2009-04-22 |
Prosidion Ltd |
Compounds for the treatment of metabolic disorders
|
|
GB0904284D0
(en)
|
2009-03-12 |
2009-04-22 |
Prosidion Ltd |
Compounds for the treatment of metabolic disorders
|
|
US20120094935A1
(en)
*
|
2009-04-09 |
2012-04-19 |
West Anthony P |
Methods for creating or identifying compounds that bind tumor necrosis factor alpha
|
|
JP5538528B2
(ja)
|
2009-06-18 |
2014-07-02 |
カディラ・ヘルスケア・リミテッド |
新規なgpr119アゴニスト
|
|
US8481731B2
(en)
*
|
2009-06-24 |
2013-07-09 |
Boehringer Ingelheim International Gmbh |
Compounds, pharmaceutical composition and methods relating thereto
|
|
TW201111361A
(en)
*
|
2009-06-24 |
2011-04-01 |
Boehringer Ingelheim Int |
New compounds, pharmaceutical composition and methods relating thereto
|
|
JP2012228181A
(ja)
*
|
2009-09-02 |
2012-11-22 |
Panasonic Corp |
脂質二重膜の産生方法、化学物質を検知可能とする方法、細胞、カリウムイオンを輸送する方法、および化学物質を検知または定量する方法
|
|
JP2012228180A
(ja)
*
|
2009-09-02 |
2012-11-22 |
Panasonic Corp |
脂質二重膜の産生方法、化学物質を検知可能とする方法、細胞、カリウムイオンを輸送する方法、および化学物質を検知または定量する方法
|
|
CA2775840C
(en)
*
|
2009-10-01 |
2018-02-06 |
Metabolex, Inc. |
Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
|
|
GB201006166D0
(en)
|
2010-04-14 |
2010-05-26 |
Prosidion Ltd |
Compounds for the treatment of metabolic disorders
|
|
GB201006167D0
(en)
|
2010-04-14 |
2010-05-26 |
Prosidion Ltd |
Compounds for the treatment of metabolic disorders
|
|
TW201209054A
(en)
|
2010-05-28 |
2012-03-01 |
Prosidion Ltd |
Novel compounds
|
|
ES2676209T3
(es)
|
2010-06-23 |
2018-07-17 |
Metabolex Inc. |
Composiciones de 5-etil-2-{4-[4-(4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
|
|
US8785463B2
(en)
|
2010-10-08 |
2014-07-22 |
Cadila Healthcare Limited |
GPR 119 agonists
|
|
WO2012066077A1
(en)
|
2010-11-18 |
2012-05-24 |
Prosidion Limited |
1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders
|
|
GB201114389D0
(en)
|
2011-08-22 |
2011-10-05 |
Prosidion Ltd |
Novel compounds
|
|
EP2718279B1
(en)
|
2011-06-09 |
2016-08-10 |
Rhizen Pharmaceuticals SA |
Novel compounds as modulators of gpr-119
|
|
EP3493807A1
(en)
|
2016-08-03 |
2019-06-12 |
CymaBay Therapeutics, Inc. |
Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
|